ATUL LTD. Q1 FY27 Results

Atul reported a sharply stronger June quarter on a consolidated basis: revenue rose 25.0% YoY to ₹1,847.95 Cr and net profit nearly doubled to ₹253.93 Cr (+91.8% YoY), lifting EPS to ₹83.32 from ₹43.40 a year ago. PBT jumped to ₹346.83 Cr from ₹177.03 Cr. Net margin expanded to ~13.7% from ~8.95% a year earlier — the profit growth ran well ahead of revenue growth, so this is a genuine margin-led print, not just a topline story. On a sequential basis PAT rose 20.3% and revenue 10.7%; note the QoQ profit comparison is against a Q4 FY26 base that carried a ₹25.41 Cr one-off gain from a labour-code provision reversal, so the underlying sequential improvement is if anything understated. Both current and year-ago quarters are free of exceptional items, so the YoY figures are clean — reported and adjusted PAT growth are the same ~92%.

The entire swing came from the Performance and Other Chemicals segment: segment revenue rose 33.8% YoY to ₹1,427.44 Cr and segment result more than doubled to ₹239.83 Cr from ₹100.00 Cr, a combination of higher volumes and recovered realisations. Life Science Chemicals was the laggard — revenue roughly flat at ₹469.23 Cr (vs ₹449.20 Cr) with segment result improving modestly to ₹92.78 Cr from ₹68.41 Cr. Gross material margin was essentially flat YoY (~51% of revenue); the margin expansion instead came from operating leverage on higher volume — power/fuel, employee and other expenses each fell as a share of revenue. The standalone entity told the same story only more starkly, with PAT more than doubling to ₹201.03 Cr on revenue of ₹1,588.60 Cr (+21.8% YoY); standalone and consolidated point the same direction, the wider standalone growth simply reflecting a lower base.

The stock went into the print at ₹6,189, down 6.5% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Management gives no formal quarterly guidance and none is on our record; a July 17 disclosure noting the company 'revised growth targets' had no published specifics, and no brokerage Q1 preview consensus was locatable, so the print cannot be scored against street. Alongside the result the board recommended a ₹30 dividend (AGM July 31) and appointed Vinayak Deshpande as an independent director effective August 1; ICICI Prudential MF crossed 5% during the quarter. The auditor's limited review is unmodified. The read into Q2 rests on whether Performance Chemicals can hold the recovered segment margin (₹239.83 Cr vs ₹100 Cr) and whether Life Science Chemicals volumes turn.